This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. Susan Green developed a stubborn ...

Vaccine effectiveness also dropped from 75.2% to 39.7% among immunocompromised individuals. Authors note that the RSV vaccine is still effective, but older and immunocompromised individuals may ...

Maternal respiratory syncytial virus vaccination appeared to be safe and effective for mothers with HIV and their infants, according to data presented at the Conference on Retroviruses and ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60-74 at high risk. Credit: MargJohnsonVA/Shutterstock. At ...

RSV vaccines showed initial high effectiveness, but protection decreased over 18 months, especially in immunocompromised individuals. The study used VHA data to evaluate vaccine effectiveness in ...

Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) vaccine, a new study finds. The report also showed that people in long-term ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that high-risk patients ages 50 to 59 be vaccinated for respiratory syncytial ...

Despite trailing in case counts, RSV sent more than 800 people to the hospital — outpacing the flu’s 314 hospitalizations and COVID-19’s 390 hospitalizations combined. Dr. Philip Heavner, pediatrician ...

Data shows that ER visits and hospital admissions for RSV have been climbing in New Jersey since early October. Currently, ER visits for RSV are “high” or “very high” in more than half of New Jersey ...